Your Antidepressant Class May Not Affect Ketamine Results

What the Research Found

A new study published in The Journal of Clinical Psychiatry in April 2026 offers meaningful reassurance for the large population of patients who take ketamine while already on an antidepressant regimen. Researchers examined clinical outcomes in patients receiving either intravenous (IV) ketamine or intranasal (IN) esketamine alongside concurrent oral antidepressants — including SSRIs, SNRIs, and other antidepressant classes — and found no statistically significant group differences in outcomes based on which antidepressant class patients were taking. In short, being on a Prozac versus an Effexor versus a Wellbutrin did not meaningfully change how well patients responded to ketamine-based treatment. You can read the original study summary at Psychiatrist.com.

This is a notable finding because clinicians and patients alike have long operated under some uncertainty here. Ketamine works primarily through NMDA receptor antagonism, a mechanism entirely distinct from the serotonin and norepinephrine pathways targeted by SSRIs and SNRIs. Yet questions persisted: could an SSRI blunt ketamine's rapid antidepressant effects? Could combining certain agents raise safety risks? This study adds to a growing body of evidence suggesting that the antidepressant you're already taking is unlikely to be a confounding variable in how you respond to ketamine.

What This Means Specifically for Oral Ketamine Tablet Users

Most published research on ketamine and antidepressant co-administration — including this study — has centered on IV infusion and intranasal esketamine (Spravato). Oral ketamine tablets occupy a different pharmacokinetic lane entirely, and that distinction matters when interpreting these findings.

When you swallow a ketamine tablet, bioavailability is considerably lower than IV or intranasal routes — typically ranging from roughly 20–30%, compared to nearly 100% for IV. The drug passes through the gut, undergoes first-pass metabolism in the liver, and a significant portion converts to norketamine, an active metabolite believed to contribute to sustained antidepressant effects. This metabolic profile means that drug interactions, including those involving antidepressants that influence hepatic enzyme activity, may theoretically play a larger role with oral dosing than with routes that bypass the gut entirely.

That said, the core message of this study — that antidepressant class does not appear to drive meaningfully different ketamine outcomes — is encouraging for oral ketamine patients. If the mechanism-level concern (that SSRIs might interfere with ketamine's antidepressant signal) doesn't hold up in IV and intranasal contexts, it becomes harder to argue that serotonergic antidepressants are pharmacodynamically blunting oral ketamine's effects either. The pathways simply don't overlap in a way that produces that outcome.

Where oral tablet users should remain attentive is on the absorption and metabolism side. Some antidepressants, particularly those that inhibit or induce CYP3A4 and CYP2B6 enzymes (which are involved in ketamine metabolism), could theoretically alter blood levels of ketamine or norketamine when taken orally. Fluvoxamine, for instance, is a potent CYP inhibitor. This is a conversation worth having with your prescribing clinician — not as a reason for alarm, but as part of dialing in your dose accurately.

The Bigger Picture: Combination Therapy Is the Norm, Not the Exception

This research reflects the real-world reality of ketamine treatment: the vast majority of patients pursuing ketamine — whether via infusion, intranasal spray, troches, or tablets — are already on at least one psychiatric medication. Ketamine is rarely a first-line monotherapy. It is most often added to an existing regimen when standard antidepressants have provided inadequate relief, which is precisely the treatment-resistant depression population these studies typically examine.

For years, some providers approached this combination cautiously, occasionally pausing antidepressants before a ketamine series or recommending washout periods. This study's findings — echoing earlier data in the same direction — support a more pragmatic clinical stance: you generally do not need to discontinue your antidepressant to pursue ketamine treatment, and doing so unnecessarily introduces its own risks, including rebound symptoms and destabilization.

For oral ketamine specifically, this is practically significant. Tablet-based protocols are often structured around longer-term, lower-dose home use — sometimes daily or several times weekly — rather than the acute infusion series model. That sustained use model is almost always layered on top of an existing antidepressant prescription. Knowing that the antidepressant class itself is not a likely confounder in outcomes gives both patients and clinicians more confidence in maintaining continuity of existing treatment while integrating oral ketamine.

As always, dosing for oral tablets should be individualized. Factors like body weight, metabolic rate, concurrent medications, and the specific formulation (immediate-release versus extended-release, tablet versus troche) all interact. The broad reassurance from this study is valuable — but it doesn't replace the need for a personalized titration conversation with your provider.